Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2016 - 2025)

Northwest Biotherapeutics' Income from Continuing Operations history spans 16 years, with the latest figure at 30582000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 30582000.0 for Q4 2025, up 9.5% from a year ago — trailing twelve months through Dec 2025 was 21877000.0 (up 13.73% YoY), and the annual figure for FY2025 was 60699000.0, up 27.55%.
  • Income from Continuing Operations for Q4 2025 was 30582000.0 at Northwest Biotherapeutics, up from 16941000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 30582000.0 in Q4 2025 to a low of 22531000.0 in Q2 2022.
  • The 5-year median for Income from Continuing Operations is 16494500.0 (2023), against an average of 11947400.0.
  • The sharpest move saw Income from Continuing Operations plummeted 148.49% in 2021, then soared 270.46% in 2024.
  • Year by year, Income from Continuing Operations stood at 11829000.0 in 2021, then crashed by 64.0% to 19399000.0 in 2022, then grew by 15.54% to 16384000.0 in 2023, then soared by 270.46% to 27928000.0 in 2024, then rose by 9.5% to 30582000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 30582000.0, 16941000.0, and 16605000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.